Tonix Pharmaceuticals, a biopharmaceutical firm, is set to showcase further findings from its Phase 3 RESILIENT trial at the 6th International Congress on Controversies in
Fibromyalgia, taking place in Brussels on March 7, 2024. The trial pertains to the efficacy of
Tonmya™, the company's fibromyalgia management drug candidate, which has already demonstrated positive outcomes in two separate Phase 3 studies.
The company, which has a robust pipeline of CNS disorder treatments, is aiming to submit a New Drug Application for Tonmya to the FDA in 2024. In addition to fibromyalgia, the drug is also being considered for treating
acute stress reactions and
fibromyalgia-type Long COVID. Tonix's portfolio is diverse, featuring a biologic designed to counter
cocaine intoxication,
TNX-1300, and a monoclonal antibody,
TNX-1500, intended for preventing
organ transplant rejection and treating
autoimmune diseases.
Tonix's commercial arm, Tonix Medicines, currently markets
Zembrace® SymTouch® and Tosymra®, treatments for
acute migraines in adults. The company is also exploring
rare diseases and
infectious diseases with its product candidates.
While the company's drug candidates are still under investigation and have not received regulatory approval, Tonix remains committed to advancing its research and development efforts. The upcoming presentation in Brussels will provide an opportunity to share more insights into the progress and potential impact of its fibromyalgia treatment.
It is important to note that the development and approval process for new pharmaceuticals is complex and subject to numerous risks and uncertainties. Tonix is aware of these challenges and continues to navigate the regulatory landscape with the goal of bringing new treatments to market.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
